Oncology Meets Immunology: The Cancer-Immunity Cycle
- 1 July 2013
- journal article
- review article
- Published by Elsevier BV in Immunity
- Vol. 39 (1), 1-10
- https://doi.org/10.1016/j.immuni.2013.07.012
Abstract
No abstract availableThis publication has 82 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaThe New England Journal of Medicine, 2012
- Cancer immunotherapyMolecular Oncology, 2012
- Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironmentCurrent Opinion in Immunology, 2011
- Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapyProceedings of the National Academy of Sciences of the United States of America, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002